文献速递临床免疫临床微生物

MiraVista IgG/IgM酶免疫法提升球孢子菌病抗体检测与诊断

Enhanced Antibody Detection and Diagnosis of Coccidioidomycosis with the MiraVista IgG and IgM Detection Enzyme Immunoassay.
PubMed 文献 · J Clin Microbiol · 2017-01-04

本研究以103例球孢子菌病病例和373例对照血清,评估MiraVista抗球孢子菌抗体酶免疫法的IgG/IgM检测性能。该法灵敏度88.3%、特异度90%,在免疫抑制状态下灵敏度仍维持;免疫扩散法灵敏度60.2%、特异度98.8%,补体结合法(62例)灵敏度66.1%但特异度未能确定。

要点

  • MiraVista抗体酶免疫法灵敏度88.3%、特异度90%,优于免疫扩散和补体结合。
  • 免疫抑制患者中该法灵敏度未受损,适合此类人群诊断。
  • 该法可实现高重复性半定量检测。

核心结论

  • MiraVista抗球孢子菌抗体酶免疫法较免疫扩散和补体结合法灵敏度更高,且在免疫抑制患者中灵敏度未受损。

研究设计与样本

  • 研究纳入103例球孢子菌病病例和373例对照的血清样本,检测IgG和IgM抗体。
  • 另取170例地方性流行区对照和44例病例的血清,在MiraVista Diagnostics用免疫扩散法检测。

主要发现

  • MiraVista抗体法灵敏度88.3%、特异度90%,在免疫抑制状态或免疫抑制治疗下灵敏度仍维持。
  • 免疫扩散法灵敏度60.2%、特异度98.8%。
  • 补体结合法(62例)灵敏度66.1%,特异度未能确定。

关键数值与推荐

  • MiraVista抗体法:灵敏度88.3%,特异度90%。
  • 免疫扩散法:灵敏度60.2%,特异度98.8%。
  • 补体结合法(62例):灵敏度66.1%,特异度未确定。

临床怎么用

  • 在球孢子菌病流行区,对社区获得性肺炎患者可考虑用MiraVista抗体酶免疫法辅助诊断。
  • 免疫抑制患者疑似球孢子菌病时,该法灵敏度不受影响,可优先选用。

局限性

  • 补体结合法仅62例,且特异度未能确定。
  • 免疫扩散法仅在部分样本(170例流行区对照和44例病例)中检测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Coccidioidomycosis is a common cause of community-acquired pneumonia in areas of the southwestern United States in which the disease is endemic. Clinical presentations range from self-limited disease to severe disseminated disease. Therefore, early and accurate diagnosis is essential to ensure appropriate treatment and monitoring. Currently available diagnostic tests have variable accuracy, particularly in certain patient populations, and new tests may offer improved accuracy for the diagnosis of coccidioidomycosis. Serum samples from 103 cases of coccidioidomycosis and 373 controls were tested for IgG and IgM antibodies using the MVista anti-Coccidioides antibody enzyme immunoassay. Serum specimens from 170 controls from areas in which the disease is endemic and 44 cases were tested by immunodiffusion at MiraVista Diagnostics. The sensitivity of the MVista antibody assay was 88.3%, and the specificity was 90%. The sensitivity was maintained in the presence of immunocompromising conditions or immunosuppressive therapies. The sensitivity of immunodiffusion was 60.2%, and the specificity was 98.8%. The sensitivity of complement fixation (62 cases) was 66.1%, but the specificity could not be determined. The MVista anti-Coccidioides antibody enzyme immunoassay offers improved sensitivity, compared with immunodiffusion and complement fixation, is not impaired in immunocompromised patients, and permits highly reproducible semiquantification.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Malo J, Holbrook E, Zangeneh T, et al. Enhanced Antibody Detection and Diagnosis of Coccidioidomycosis with the MiraVista IgG and IgM Detection Enzyme Immunoassay. J Clin Microbiol. 2017. PMID: 28053216. doi:10.1128/JCM.01880-16

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。